Gilead's Trodelvy meets primary endpoint in HR+/HER2- metastatic breast cancer trial
Justin Sullivan/Getty Images News


Gilead Sciences' (NASDAQ:GILD) Trodelvy (sacituzumab) met its primary endpoint in a late-stage trial in patients with HR+/HER2- metastatic breast cancer.
Shares are down 4% in premarket trading.
The primary endpoint was a statistically significant improvement in progression-free survival ("PFS") compared to physicianâs choice of chemotherapy. The trial targeted a 30% reduction in the risk of disease progression or death.

The trial enrolled patients who had undergone multiple lines of prior therapy.
The study will continue to evaluate overall survival, a secondary endpoint. An interim analysis of this endpoint indicated a trend toward improvement.
Trodelvy is currently approved for metastatic triple-negative breast cancer
Read why Seeking Alpha contributor Out of Ignore rates Gilead (GILD) a hold.